RxDoctor Payments DataLook up a doctor →

Asim Roy, MD

Sleep Medicine · Dublin, OHNPI 1639159767

Payments from drug & device makers

$2,217,394in general payments, 2019–2025

Across 1,367 payments — averaging $1622.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Jazz Pharmaceuticals Inc.$903K
  • Takeda Pharmaceuticals U.S.A., Inc.$358K
  • Inspire Medical Systems, Inc.$283K
  • Harmony Biosciences LLC$223K
  • Avadel CNS Pharmaceuticals, LLC$165K
  • Noctrix Health, Inc.$80K
  • plus $206K from 22 others

What the payments were for

  • Consulting fees$266,45240%
  • Speaking & faculty fees$336,53351%
  • Travel & lodging$43,1526%
  • Food & beverage$19,4613%
  • Education$6520%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,217,394 in reported general payments places this provider in the 95th percentile of 94 sleep medicine providers in Ohio.

See all sleep medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$244,544
Medicare patients
593
Services billed
2,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WakixPitolisant Hcl60$873,805
SunosiSolriamfetol Hcl32$33,436
Modafinil44$18,315
QuviviqDaridorexant Hcl22$10,631
DayvigoLemborexant13$5,698
Atomoxetine Hcl18$4,146
Armodafinil28$1,932
Pregabalin32$702
Trazodone Hcl83$613
Gabapentin51$565
Doxepin Hcl26$534
Zolpidem Tartrate ErZolpidem Tartrate21$460
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine12$445
Methadone Hcl34$420
Eszopiclone23$282

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$222,630$873,80560 claims
Axsome Therapeutics, Inc.Sunosi$12,150$33,43632 claims
Idorsia Pharmaceuticals US IncQuviviq$31$10,63122 claims
Eisai Inc.Dayvigo$16,222$5,69813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 94 sleep medicine providers in Ohio.

Other sleep medicine in Dublin

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →